NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Management of subclinical hypothyroidism
Evidence review G
NICE Guideline, No. 145
Authors
National Guideline Centre (UK).Management of subclinical hypothyroidism
1.1. Review question: What is the clinical and cost-effectiveness of treating subclinical hypothyroidism?
1.2. Introduction
Subclinical hypothyroidism (SCH) is a biochemical state in which the serum thyroid stimulating hormone (TSH) is elevated above the reference range whilst the concentrations of circulating free thyroid hormones (FT4, FT3) are within the reference range for the population. It is more common in women and becomes increasingly prevalent with age, such that around 5% of people over 70 years of age, and 10% of people over 80 may manifest SCH.
In some people SCH may be a transient phenomenon reflecting non-thyroidal illness or drug effects, but in others it may be an early manifestation of a disease process such as Hashimoto thyroiditis - in this situation the biochemical picture represents a state of compensated or mild hypothyroidism in which the circulating thyroid hormones remain within the reference range owing to increased thyroid gland stimulation by TSH.
As serum free thyroid hormones are within the reference range for the population in SCH there is uncertainty as to whether people benefit from increasing their circulating thyroid hormones with replacement therapy. Symptoms of hypothyroidism are non-specific and common in the euthyroid population, meaning that clinicians cannot be confident they have treated symptoms caused by hypothyroidism in someone with SCH. This leaves open several questions about the optimal management of people with persistent SCH.
1.3. PICO table
For full details see the review protocol in Appendix A:.
1.4. Clinical evidence
1.4.1. Included studies
Six RCTs were included in the review;19,24,28,34,35,40 these are summarised in Table 2 below. Evidence from these studies is summarised in the clinical evidence summary below (Table 3). One Cochrane review was identified in this area45, the studies included in this publication were checked against the protocol and were not included in this review.
All six RCTs compared T4 with placebo.
No relevant clinical trials comparing T3, natural thyroid extract, and iodine or selenium supplementation with any other intervention or placebo were identified.
Five included studies were in the adult (18–65) age stratum, whereas one study was in the older adult (>65) age stratum.40 The majority of participants were female in four studies;28, 34, 35, 40 whereas, the remaining two studies were conducted exclusively on female participants.19, 24 Four RCTs were conducted on a treatment naïve population. In one RCT participants having received thyroid medication in the past 3 months were excluded24 whereas whether participants had received previous treatment was not specified in one RCT35 The primary cause of subclinical hypothyroidism was autoimmune thyroiditis in at least four studies19, 24, 34, 35; whereas this was not reported in the remaining two studies.28, 40
The follow-up period of the included studies was from 3 to 12 months.
See also the study selection flow chart in Appendix C:, study evidence tables in Appendix D:, forest plots in Appendix E: and GRADE tables in Appendix F:.
1.4.2. Excluded studies
See the excluded studies list in Appendix J:.
1.4.3. Summary of clinical studies included in the evidence review
See Appendix D: for full evidence tables.
1.4.4. Quality assessment of clinical studies included in the evidence review
See Appendix F: for full GRADE tables.
1.5. Economic evidence
1.5.1. Included studies
No relevant health economic studies were identified.
1.5.2. Excluded studies
No health economic studies that were relevant to this question were excluded due to assessment of limited applicability or methodological limitations.
See also the health economic study selection flow chart in appendix G.
1.5.3. Health economic modelling
This area was not prioritised for new cost-effectiveness analysis.
1.5.4. Resource costs
Relevant unit costs are provided below to aid consideration of cost effectiveness.
1.6. Evidence statements
1.6.1. Clinical evidence statements
1.6.1.1. Levothyroxine vs placebo in adults
No clinically important difference was identified for hypothyroid dependent quality of life (1 study, moderate quality), quality of life measures: general health, physical functioning, social functioning (1 study, very low quality), for depression (2 studies, moderate quality), hypothyroid symptoms (2 studies, high quality) and TSH suppression (2 studies, very low quality).
There was a clinically important benefit of levothyroxine for quality of life measures: role physical functioning and bodily pain (1 study, moderate quality), and role emotional functioning (1 study, low quality).
There was a clinically important harm of levothyroxine for quality of life-mental health and vitality (1 study, very low quality).
No evidence was identified for mortality; cardiovascular morbidity-ischemic heart disease; heart failure; arrhythmias; osteoporosis; impaired cognitive function; experience of care; healthcare contacts; growth.
1.6.1.2. Levothyroxine vs placebo in older adults
No clinically important difference was identified for quality of life measured by the EQ-5D (1 study, moderate quality), quality of life measured by the EQ VAS, hypothyroid symptoms and hyperthyroid symptoms (1 study, high quality).
No evidence was identified for mortality; cardiovascular morbidity-ischemic heart disease; heart failure; arrhythmias; osteoporosis; impaired cognitive function; depression; experience of care; healthcare contacts; growth; TSH suppression.
1.6.2. Health economic evidence statements
- No relevant economic evaluations were identified.
1.7. The committee’s discussion of the evidence
1.7.1. Interpreting the evidence
1.7.1.1. The outcomes that matter most
The committee agreed that the critical outcomes for this review were mortality and quality of life. Important outcomes were cardiovascular morbidity, arrhythmias, osteoporosis, impaired cognitive function, depression, experience of care, healthcare contacts, symptom scores, growth and TSH suppression.
No clinical evidence was found for mortality. Thus, it was agreed that decision making would be based on quality of life and the important outcomes for which evidence was available.
1.7.1.2. The quality of the evidence
The quality of the evidence ranged from very low to high, being of very low quality for the majority of outcomes. Evidence was typically downgraded for risk of bias which was often attributed to selection bias. Across comparisons, evidence for certain outcomes was also downgraded for imprecision. Overall, the studies included in this review were of relatively short term follow-up, with participants followed up for up to 12 months, while they were receiving the interventions.
Levothyroxine vs placebo in adults
The quality of evidence for the use of levothyroxine compared to placebo in adults ranged from very low to high, the majority being of very low quality. The evidence was downgraded mostly due to risk of bias and occasionally due to imprecision. Studies relative to the adult age stratum had a follow up ranging from three to 12 months.
Levothyroxine vs placebo in older adults
The quality of the majority of the evidence for the use of levothyroxine compared to placebo in older adults was high with the exception of one outcome for which the quality of the evidence was moderate and downgraded due to imprecision. Within this comparison, participants of the older age stratum were followed up for 12 months.
1.7.1.3. Benefits and harms
Levothyroxine vs placebo in adults
The evidence showed there was a clinically important benefit with levothyroxine compared to placebo for three quality of life domains: role-physical, role-emotional and bodily pain.
The evidence also showed that there was a clinically important harm with levothyroxine compared to placebo in terms of two quality of life domains, mental health and vitality.
No clinically important difference was found as a result of levothyroxine treatment compared to placebo for hypothyroid dependent quality of life, three quality of life domains: general health, physical functioning and social functioning, depression, hypothyroid symptoms and TSH suppression.
The committee noted that the absence of a clinically important effect could be at least partially attributed to the relatively short-term follow up periods of the studies included in this comparison, which ranged from three to 12 months. They felt that this was likely to be insufficient to observe a clinical difference that is likely to emerge later after treatment. Particularly in regards to depression and symptoms, there was agreement that a longer follow up would be required to draw conclusions about the effect of treatment with levothyroxine for adults with subclinical hypothyroidism.
It was also noted that the dosing strategies of some studies included low doses of levothyroxine that did not reflect current UK practice (starting dose is typically around 100 µg/d), and that this may undermine the effect of levothyroxine on the outcomes measured in the current evidence.
The committee noted the variability in the baseline TSH levels of patients in the studies included in this review. They specified that a TSH greater than 10 mlU/litre would be much less likely to normalise than a lower TSH and agreed on the appropriateness of using this cut off to determine treatment with levothyroxine.
It was raised that an overreliance on TSH levels in decision making about treatment that is most often the case in clinical practice may be problematic, and that other factors, including patients’ symptomatology are to influence their need for treatment. The committee felt that a trial period of treatment of 6 months would be appropriate for symptomatic patients with TSH lower than the 10 mlU/litre cut-off.
The importance of making recommendations for both providing but also stopping treatment, in cases where no apparent benefit in symptoms is achieved was emphasised. There was agreement that whether or not TSH returns to normal is a factor indicating the success of treatment but that symptoms are also important.
The committee highlighted that the presence of antibodies may also influence the likelihood of TSH to return to normal. Within this context, the committee agreed on the importance of considering factors including antibody status and previous thyroid surgery that may suggest an underlying thyroid disease when it comes to the decision of whether or not to offer treatment for subclinical hypothyroidism.
Levothyroxine vs placebo in older adults
Compared to placebo, treatment with levothyroxine did not lead to a clinically important difference in two separate quality of life measures, hypothyroid symptoms and hyperthyroid symptoms.
The committee noted that the evidence for the use of levothyroxine in older adults was underpinned by one study and that a considerable proportion of the participants in this study were asymptomatic and identified based on incidental findings. The committee agreed that it was plausible that the benefits of treatment would be greater in those who had symptoms at baseline.
1.7.2. Cost effectiveness and resource use
There was no health economic evidence identified for this review question, therefore recommendations were based on consensus around treating subclinical hypothyroidism. Unit costs were presented for different doses of levothyroxine as found in the included clinical studies to aid the committee members in their qualitative judgement in regards to the cost effectiveness.
Levothyroxine vs placebo in adults
Although the quality of life evidence was mixed the committee thought that targeting treatment at specific groups that were more likely to benefit would maximise the likelihood of treatment being cost effective.. Overall, treating symptomatic patients compared to treating patients according to their TSH levels only, is likely to be cost saving. Firstly, because only those who need treatment will be considered, this reduces the number of people being treated unnecessarily, and secondly, people who are considered for treatment will receive a 6 month trial of treatment, after which they will be re-assessed and if no improvement is seen treatment can be stopped. This reduces prescriptions, unnecessary continuation of treatment, compliance issues, and costs.
Furthermore, the committee noted that the current practice for treating subclinical hypothyroidism is done by giving 100µcg daily of levothyroxine tablet (£1.03 per month, BNF, December 2017), which is the cheapest treatment option.
Levothyroxine vs placebo in older adults
The committee did not recommend treatment with levothyroxine for older adults, other than when the TSH was above the reference range but lower than 10 mIU/litre, which is in line with current practice.
1.7.3. Other factors the committee took into account
The committee acknowledged that patients often request treatments with selenium or iodine supplementation. Considering the lack of evidence in regards to those treatments and the frequency with which patients request them, the committee agreed to make research recommendations to investigate their effectiveness for treating subclinical hypothyroidism.
References
- 1.
- Abreu IM, Lau E, de Sousa Pinto B, Carvalho D. Subclinical hypothyroidism: to treat or not to treat, that is the question! A systematic review with meta-analysis on lipid profile. Endocrine Connections. 2017; 6(3):188–199 [PMC free article: PMC5428911] [PubMed: 28249936]
- 2.
- Aghili R, Khamseh ME, Malek M, Hadian A, Baradaran HR, Najafi L et al. Changes of subtests of Wechsler Memory Scale and cognitive function in subjects with subclinical hypothyroidism following treatment with levothyroxine. Archives of Medical Science. 2012; 8(6):1096–101 [PMC free article: PMC3542502] [PubMed: 23319987]
- 3.
- Akintola AA, Jansen SW, van Bodegom D, van der Grond J, Westendorp RG, de Craen AJ et al. Subclinical hypothyroidism and cognitive function in people over 60 years: a systematic review and meta-analysis. Frontiers in Aging Neuroscience. 2015; 7:150 [PMC free article: PMC4531303] [PubMed: 26321946]
- 4.
- Angermayr L, Clar C. Iodine supplementation for preventing iodine deficiency disorders in children. Cochrane Database of Systematic Reviews 2004, Issue 2. Art. No.: CD003819. DOI: 10.1002/14651858.CD003819.pub2. [PubMed: 15106221] [CrossRef]
- 5.
- Appelhof BC, Peeters RP, Wiersinga WM, Visser TJ, Wekking EM, Huyser J et al. Polymorphisms in type 2 deiodinase are not associated with well-being, neurocognitive functioning, and preference for combined thyroxine/3,5,3′-triiodothyronine therapy. Journal of Clinical Endocrinology and Metabolism. 2005; 90(11):6296–9 [PubMed: 16144953]
- 6.
- BMJ Group and the Royal Pharmaceutical Society of Great Britain. British National Formulary. Available from: https://www
.evidence .nhs.uk/formulary/bnf/current Last accessed: 04 April 2017 - 7.
- Cabral MD, Teixeira P, Soares D, Leite S, Salles E, Waisman M. Effects of thyroxine replacement on endothelial function and carotid artery intima-media thickness in female patients with mild subclinical hypothyroidism. Clinics (Sao Paulo, Brazil). 2011; 66(8):1321–8 [PMC free article: PMC3161206] [PubMed: 21915478]
- 8.
- Caraccio N, Ferrannini E, Monzani F. Lipoprotein profile in subclinical hypothyroidism: response to levothyroxine replacement, a randomized placebo-controlled study. Journal of Clinical Endocrinology and Metabolism. 2002; 87(4):1533–8 [PubMed: 11932277]
- 9.
- Caraccio N, Natali A, Sironi A, Baldi S, Frascerra S, Dardano A et al. Muscle metabolism and exercise tolerance in subclinical hypothyroidism: a controlled trial of levothyroxine. Journal of Clinical Endocrinology and Metabolism. 2005; 90(7):4057–62 [PubMed: 15855263]
- 10.
- Cassio A, Cacciari E, Cicognani A, Damiani G, Missiroli G, Corbelli E et al. Treatment for congenital hypothyroidism: thyroxine alone or thyroxine plus triiodothyronine? Pediatrics. 2003; 111(5 Pt 1):1055–60 [PubMed: 12728088]
- 11.
- Cerbone M, Capalbo D, Wasniewska M, Alfano S, Raso GM, Oliviero U et al. Effects of L-thyroxine treatment on early markers of atherosclerotic disease in children with subclinical hypothyroidism. European Journal of Endocrinology. 2016; 175(1):11–19 [PubMed: 27068687]
- 12.
- Cooper DS, Halpern R, Wood LC, Levin AA, Ridgway EC. L-Thyroxine therapy in subclinical hypothyroidism. A double-blind, placebo-controlled trial. Annals of Internal Medicine. 1984; 101(1):18–24 [PubMed: 6428290]
- 13.
- Fadeyev VV, Sytch J, Kalashnikov V, Rojtman A, Syrkin A, Melnichenko G. Levothyroxine replacement therapy in patients with subclinical hypothyroidism and coronary artery disease. Endocrine Practice. 2006; 12(1):5–17 [PubMed: 16524858]
- 14.
- Feller M, Snel M, Moutzouri E, Bauer DC, de Montmollin M, Aujesky D et al. Association of Thyroid Hormone Therapy With Quality of Life and Thyroid-Related Symptoms in Patients With Subclinical Hypothyroidism: A Systematic Review and Meta-analysis. JAMA. 2018; 320(13):1349–1359 [PMC free article: PMC6233842] [PubMed: 30285179]
- 15.
- Ineck BA, Ng TM. Effects of subclinical hypothyroidism and its treatment on serum lipids. Annals of Pharmacotherapy. 2003; 37(5):725–30 [PubMed: 12708952]
- 16.
- Iqbal A, Jorde R, Figenschau Y. Serum lipid levels in relation to serum thyroid-stimulating hormone and the effect of thyroxine treatment on serum lipid levels in subjects with subclinical hypothyroidism: the Tromso Study. Journal of Internal Medicine. 2006; 260(1):53–61 [PubMed: 16789979]
- 17.
- Joint Formulary Committee. British National Formulary (BNF) December 2017 update. 2017. Available from: http://www
.bnf.org.uk Last accessed: 01/03/2018 - 18.
- Jorde R, Waterloo K, Storhaug H, Nyrnes A, Sundsfjord J, Jenssen TG. Neuropsychological function and symptoms in subjects with subclinical hypothyroidism and the effect of thyroxine treatment. Journal of Clinical Endocrinology and Metabolism. 2006; 91(1):145–53 [PubMed: 16263815]
- 19.
- Kong WM, Sheikh MH, Lumb PJ, Naoumova RP, Freedman DB, Crook M et al. A 6-month randomized trial of thyroxine treatment in women with mild subclinical hypothyroidism. American Journal of Medicine. 2002; 112(5):348–54 [PubMed: 11904108]
- 20.
- Koroglu BK, Bagci O, Ersoy IH, Aksu O, Balkarli A, Alanoglu E et al. Effects of Levothyroxine Treatment on Cardiovascular Risk Profile and Carotid Intima Media Thickness in Patients with Subclinica Hypothyroidism. Acta Endocrinologica. 2012; 8(3):433–442
- 21.
- Li X, Meng Z, Jia Q, Ren X. Effect of L-thyroxine treatment versus a placebo on serum lipid levels in patients with sub-clinical hypothyroidism. Biomedical Reports. 2016; 5(4):443–449 [PMC free article: PMC5038512] [PubMed: 27699011]
- 22.
- Mainenti MR, Vigario PS, Teixeira PF, Maia MD, Oliveira FP, Vaisman M. Effect of levothyroxine replacement on exercise performance in subclinical hypothyroidism. Journal of Endocrinological Investigation. 2009; 32(5):470–3 [PubMed: 19468264]
- 23.
- Martins RM, Fonseca RH, Duarte MM, Reuters VS, Ferreira MM, Almeida C et al. Impact of subclinical hypothyroidism treatment in systolic and diastolic cardiac function. Arquivos Brasileiros de Endocrinologia e Metabologia. 2011; 55(7):460–7 [PubMed: 22147094]
- 24.
- Meier C, Staub JJ, Roth CB, Guglielmetti M, Kunz M, Miserez AR et al. TSH-controlled L-thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism: a double blind, placebo-controlled trial (Basel Thyroid Study). Journal of Clinical Endocrinology and Metabolism. 2001; 86(10):4860–6 [PubMed: 11600554]
- 25.
- Monzani F, Caraccio N, Kozakowa M, Dardano A, Vittone F, Virdis A et al. Effect of levothyroxine replacement on lipid profile and intima-media thickness in subclinical hypothyroidism: a double-blind, placebo-controlled study. Journal of Clinical Endocrinology and Metabolism. 2004; 89(5):2099–106 [PubMed: 15126526]
- 26.
- Monzani F, Di Bello V, Caraccio N, Bertini A, Giorgi D, Giusti C et al. Effect of levothyroxine on cardiac function and structure in subclinical hypothyroidism: a double blind, placebo-controlled study. Journal of Clinical Endocrinology and Metabolism. 2001; 86(3):1110–5 [PubMed: 11238494]
- 27.
- Nagasaki T, Inaba M, Yamada S, Shirakawa K, Nagata Y, Kumeda Y et al. Decrease of brachial-ankle pulse wave velocity in female subclinical hypothyroid patients during normalization of thyroid function: a double-blind, placebo-controlled study. European Journal of Endocrinology. 2009; 160(3):409–15 [PubMed: 19114542]
- 28.
- Najafi L, Malek M, Hadian A, Ebrahim Valojerdi A, Khamseh ME, Aghili R. Depressive symptoms in patients with subclinical hypothyroidism-the effect of treatment with levothyroxine: a double-blind randomized clinical trial. Endocrine Research. 2015; 40(3):121–6 [PubMed: 25775223]
- 29.
- National Institute for Health and Care Excellence. Developing NICE guidelines: the manual [updated October 2018]. London. National Institute for Health and Care Excellence, 2014. Available from: http://www
.nice.org.uk /article/PMG20/chapter /1%20Introduction%20and%20overview - 30.
- Ng SM, Anand D, Weindling AM. High versus low dose of initial thyroid hormone replacement for congenital hypothyroidism. Cochrane Database of Systematic Reviews 2009, Issue 1. Art. No.: CD006972. DOI: 10.1002/14651858.CD006972.pub2. [PMC free article: PMC7387754] [PubMed: 19160309] [CrossRef]
- 31.
- Nystrom E, Caidahl K, Fager G, Wikkelso C, Lundberg PA, Lindstedt G. A double-blind cross-over 12-month study of L-thyroxine treatment of women with ‘subclinical’ hypothyroidism. Clinical Endocrinology. 1988; 29(1):63–75 [PubMed: 3073880]
- 32.
- Parle J, Roberts L, Wilson S, Pattison H, Roalfe A, Haque MS et al. A randomized controlled trial of the effect of thyroxine replacement on cognitive function in community-living elderly subjects with subclinical hypothyroidism: the Birmingham Elderly Thyroid study. Journal of Clinical Endocrinology and Metabolism. 2010; 95(8):3623–32 [PubMed: 20501682]
- 33.
- Pollock MA, Sturrock A, Marshall K, Davidson KM, Kelly CJ, McMahon AD et al. Thyroxine treatment in patients with symptoms of hypothyroidism but thyroid function tests within the reference range: randomised double blind placebo controlled crossover trial. BMJ. 2001; 323(7318):891–5 [PMC free article: PMC58535] [PubMed: 11668132]
- 34.
- Razvi S, Ingoe L, Keeka G, Oates C, McMillan C, Weaver JU. The beneficial effect of L-thyroxine on cardiovascular risk factors, endothelial function, and quality of life in subclinical hypothyroidism: randomized, crossover trial. Journal of Clinical Endocrinology and Metabolism. 2007; 92(5):1715–23 [PubMed: 17299073]
- 35.
- Reuters VS, Almeida Cde P, Teixeira Pde F, Vigario Pdos S, Ferreira MM, Castro CL et al. Effects of subclinical hypothyroidism treatment on psychiatric symptoms, muscular complaints, and quality of life. Arquivos Brasileiros de Endocrinologia e Metabologia. 2012; 56(2):128–36 [PubMed: 22584566]
- 36.
- Ross DS. Bone density is not reduced during the short-term administration of levothyroxine to postmenopausal women with subclinical hypothyroidism: a randomized, prospective study. American Journal of Medicine. 1993; 95(4):385–8 [PubMed: 8213870]
- 37.
- Ruggeri RM, Trimarchi F, Biondi B. L-Thyroxine replacement therapy in the frail elderly: A challenge in clinical practice. European Journal of Endocrinology. 2017; 177(4):R199–R217 [PubMed: 28566447]
- 38.
- Segna D, Bauer DC, Feller M, Schneider C, Fink HA, Aubert CE et al. Association between subclinical thyroid dysfunction and change in bone mineral density in prospective cohorts. Journal of Internal Medicine. 2017; 283(1):56–72 [PMC free article: PMC5739958] [PubMed: 29034571]
- 39.
- Shatynska-Mytsyk I, Rodrigo L, Cioccocioppo R, Petrovic D, Lakusic N, Compostella L et al. The impact of thyroid hormone replacement therapy on left ventricular diastolic function in patients with subclinical hypothyroidism. Journal of Endocrinological Investigation. 2016; 39(6):709–713 [PubMed: 25740068]
- 40.
- Stott DJ, Rodondi N, Kearney PM, Ford I, Westendorp RGJ, Mooijaart SP et al. Thyroid hormone therapy for older adults with subclinical hypothyroidism. New England Journal of Medicine. 2017; 376(26):2534–2544 [PubMed: 28402245]
- 41.
- Sun J, Yao L, Fang Y, Yang R, Chen Y, Yang K et al. Relationship between Subclinical Thyroid Dysfunction and the Risk of Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Prospective Cohort Studies. International Journal of Endocrinology Print. 2017; 2017:8130796 [PMC free article: PMC5610794] [PubMed: 29081800]
- 42.
- Taylor PN, Okosieme OE, Dayan CM, Lazarus JH. Impact of iodine supplementation in mild-to-moderate iodine deficiency: Systematic review and meta-analysis. European Journal of Endocrinology. 2014; 170(1):R1–R15 [PubMed: 24088547]
- 43.
- Teixeira PF, Reuters VS, Ferreira MM, Almeida CP, Reis FA, Melo BA et al. Treatment of subclinical hypothyroidism reduces atherogenic lipid levels in a placebo-controlled double-blind clinical trial. Hormone and Metabolic Research. 2008; 40(1):50–5 [PubMed: 18085502]
- 44.
- Valizadeh M, Seyyedmajidi MR, Momtazi S, Musavi Nasab N. The efficacy of combined levothyroxine plus liothyronine with levothyroxine alone in primary hypothyroidism: a randomized controlled trial. Iranian journal of endocrinology and metabolism. 2009; 10(5):465–471
- 45.
- Villar HCCE, Saconato H, Valente O, Atallah ÁN. Thyroid hormone replacement for subclinical hypothyroidism. Cochrane Database of Systematic Reviews 2007, Issue 3. Art. No.: CD003419. DOI: 10.1002/14651858.CD003419.pub2. [PMC free article: PMC6610974] [PubMed: 17636722] [CrossRef]
- 46.
- Wasniewska M, Corrias A, Aversa T, Valenzise M, Mussa A, De Martino L et al. Comparative evaluation of therapy with L-thyroxine versus no treatment in children with idiopathic and mild subclinical hypothyroidism. Hormone research in pdiatrics. 2012; 77(6):376–81 [PubMed: 22699818]
- 47.
- Yazici M, Gorgulu S, Sertbas Y, Erbilen E, Albayrak S, Yildiz O et al. Effects of thyroxin therapy on cardiac function in patients with subclinical hypothyroidism: index of myocardial performance in the evaluation of left ventricular function. International Journal of Cardiology. 2004; 95(2–3):135–43 [PubMed: 15193811]
- 48.
- Yetmis M, Kazancioglu R, Erkoc R, Tukek T, Peru C, Cikrkcioglu MA. Changes in lipid profile and body mass index in patients with subclinical hypothyroidism: Evaluation of L-Thyroxine treatment. Haseki Tip Bulteni. 2011; 49(4):131–135
- 49.
- Zhao M, Liu L, Wang F, Yuan Z, Zhang X, Xu C et al. A Worthy Finding: Decrease in Total Cholesterol and Low-Density Lipoprotein Cholesterol in Treated Mild Subclinical Hypothyroidism. Thyroid. 2016; 26(8):1019–29 [PubMed: 27270263]
- 50.
- Zhao T, Chen B, Zhou Y, Wang X, Zhang Y, Wang H et al. Effect of levothyroxine on the progression of carotid intima-media thickness in subclinical hypothyroidism patients: a meta-analysis. BMJ Open. 2017; 7(10):e016053 [PMC free article: PMC5665330] [PubMed: 29061604]
- 51.
- Zhu L, Bai X, Teng WP, Shan ZY, Wang WW, Fan CL et al. [Effects of selenium supplementation on antibodies of autoimmune thyroiditis]. Chinese Medical Journal (Taipei). 2012; 92(32):2256–2260 [PubMed: 23158484]
Appendices
Appendix A. Review protocols
Table 5
| ID | Field | Content |
|---|---|---|
| I | Review question | What is the clinical and cost effectiveness of treating subclinical hypothyroidism? |
| II | Type of review question |
Intervention A review of health economic evidence related to the same review question was conducted in parallel with this review. For details see the health economic review protocol for this NICE guideline. |
| III | Objective of the review | Determine the most clinically and cost effective way to treat subclinical hypothyroidism |
| IV | Eligibility criteria – population / disease / condition / issue / domain | People diagnosed with subclinical hypothyroidism (TSH greater than upper limit of context specific reference range, T3/T4 within reference range) |
| V | Eligibility criteria – intervention(s) / exposure(s) / prognostic factor(s) |
T3 T4 – initiation at high dose T4 – initiation via gradual titration Combination of T3 & T4 Natural thyroid extract (mammalian only) Iodine supplementation Selenium supplementation Placebo |
| VI | Eligibility criteria – comparator(s) / control or reference (gold) standard | Any of above vs any other, in isolation or combination |
| VII | Outcomes and prioritisation | Critical
|
| VIII | Eligibility criteria – study design |
|
| IX | Other inclusion exclusion criteria |
|
| X | Proposed sensitivity / subgroup analysis, or meta-regression | Stratifications
|
| XI | Selection process – duplicate screening / selection / analysis |
|
| XII | Data management (software) |
|
| XIII | Information sources – databases and dates |
|
| XIV | Identify if an update | Not an update |
| XV | Author contacts |
https://www |
| XVI | Highlight if amendment to previous protocol | Not an amendment |
| XVII | Search strategy – for one database | For details please see Appendix B:. |
| XVIII | Data collection process – forms / duplicate | A standardised evidence table format was used, and published as an appendix of the evidence report. |
| XIX | Data items – define all variables to be collected | For details please see evidence tables in Appendix D: (clinical evidence tables) or Appendix H: (health economic evidence tables). |
| XX | Methods for assessing bias at outcome / study level |
Standard study checklists were used to critically appraise individual studies. For details please see section 6.2 of Developing NICE guidelines: the manual The risk of bias across all available evidence was evaluated for each outcome using an adaptation of the ‘Grading of Recommendations Assessment, Development and Evaluation (GRADE) toolbox’ developed by the international GRADE working group http://www |
| XXI | Criteria for quantitative synthesis | For details please see section 6.4 of Developing NICE guidelines: the manual. |
| XXII | Methods for quantitative analysis – combining studies and exploring (in)consistency | For details please see the separate Methods report for this guideline. |
| XXIII | Meta-bias assessment – publication bias, selective reporting bias | For details please see section 6.2 of Developing NICE guidelines: the manual. |
| XXIV | Confidence in cumulative evidence | For details please see sections 6.4 and 9.1 of Developing NICE guidelines: the manual. |
| XXV | Rationale / context – what is known | For details please see the introduction to the evidence review. |
| XXVI | Describe contributions of authors and guarantor |
A multidisciplinary committee developed the evidence review. The committee was convened by the National Guideline Centre (NGC) and chaired by Sarah Fishburn in line with section 3 of Developing NICE guidelines: the manual. Staff from NGC undertook systematic literature searches, appraised the evidence, conducted meta-analysis and cost-effectiveness analysis where appropriate, and drafted the evidence review in collaboration with the committee. For details please see Developing NICE guidelines: the manual. |
| XXVII | Sources of funding / support | NGC is funded by NICE and hosted by the Royal College of Physicians. |
| XXVIII | Name of sponsor | NGC is funded by NICE and hosted by the Royal College of Physicians. |
| XXIX | Roles of sponsor | NICE funds NGC to develop guidelines for those working in the NHS, public health and social care in England. |
| XXX | PROSPERO registration number | Not registered |
Table 6Health economic review protocol
| Review question | All questions – health economic evidence |
|---|---|
| Objectives | To identify health economic studies relevant to any of the review questions. |
| Search criteria |
|
| Search strategy | A health economic study search will be undertaken using population-specific terms and a health economic study filter – see Appendix B: below. |
| Review strategy |
Studies not meeting any of the search criteria above will be excluded. Studies published before 2003, abstract-only studies and studies from non-OECD countries or the USA will also be excluded. Each remaining study will be assessed for applicability and methodological limitations using the NICE economic evaluation checklist which can be found in appendix H of Developing NICE guidelines: the manual (2014).29 Inclusion and exclusion criteria
The health economist will make a decision based on the relative applicability and quality of the available evidence for that question, in discussion with the guideline committee if required. The ultimate aim is to include health economic studies that are helpful for decision-making in the context of the guideline and the current NHS setting. If several studies are considered of sufficiently high applicability and methodological quality that they could all be included, then the health economist, in discussion with the committee if required, may decide to include only the most applicable studies and to selectively exclude the remaining studies. All studies excluded on the basis of applicability or methodological limitations will be listed with explanation in the excluded health economic studies appendix below. The health economist will be guided by the following hierarchies. Setting:
|
Appendix B. Literature search strategies
The literature searches for this review are detailed below and complied with the methodology outlined in Developing NICE guidelines: the manual 2014, updated 2018 https://www.nice.org.uk/guidance/pmg20/resources/developing-nice-guidelines-the-manual-pdf-72286708700869
For more detailed information, please see the Methodology Review.
B.1. Clinical search literature search strategy
Searches were constructed using a PICO framework where population (P) terms were combined with Intervention (I) and in some cases Comparison (C) terms. Outcomes (O) are rarely used in search strategies for interventions as these concepts may not be well described in title, abstract or indexes and therefore difficult to retrieve. Search filters were applied to the search where appropriate.
| Database | Dates searched | Search filter used |
|---|---|---|
| Medline (OVID) | 1946 – 07 January 2019 |
Exclusions Randomised controlled trials Systematic review studies |
| Embase (OVID) | 1974 – 07 January 2019 |
Exclusions Randomised controlled trials Systematic review studies |
| The Cochrane Library (Wiley) |
Cochrane Reviews to 2019 Issue 1 or 12 CENTRAL to 2019 Issue 1 or 12 DARE, and NHSEED to 2015 Issue 2 of 4 HTA to 2016 Issue 2 of 4 | None |
Medline (Ovid) search terms
| 1. | exp thyroid diseases/ |
| 2. | hyperthyroid*.ti,ab. |
| 3. | hypothyroid*.ti,ab. |
| 4. | thyrotoxicosis.ti,ab. |
| 5. | (thyroid adj3 (swell* or dysfunction* or enlarg* or nodule* or node* or disease* or condition* or disorder*)).ti,ab. |
| 6. | or/1–5 |
| 7. | letter/ |
| 8. | editorial/ |
| 9. | news/ |
| 10. | exp historical article/ |
| 11. | Anecdotes as Topic/ |
| 12. | comment/ |
| 13. | case report/ |
| 14. | (letter or comment*).ti. |
| 15. | or/7–14 |
| 16. | randomized controlled trial/ or random*.ti,ab. |
| 17. | 15 not 16 |
| 18. | animals/ not humans/ |
| 19. | exp Animals, Laboratory/ |
| 20. | exp Animal Experimentation/ |
| 21. | exp Models, Animal/ |
| 22. | exp Rodentia/ |
| 23. | (rat or rats or mouse or mice).ti. |
| 24. | or/17–23 |
| 25. | 6 not 24 |
| 26. | limit 25 to English language |
| 27. | ((iodine or selenium) adj2 supplement*).ti,ab. |
| 28. | (desiccated adj3 (thyroid or hormone* or extract or extracts)).ti,ab. |
| 29. | (thyroid adj2 (extract or extracts)).ti,ab. |
| 30. | (natural adj4 thyroid).ti,ab. |
| 31. | (natural adj3 (extract or extracts)).ti,ab. |
| 32. | armour*.ti,ab. |
| 33. | (thyroxine or levothyroxine or liothyronine or triiodothyronine or tri-iodothyronine).ti,ab. |
| 34. | Thyroxine/ or Triiodothyronine/ |
| 35. | (T3 or T4).ti,ab. |
| 36. | (TSH or thyroid stimulating hormone or thyrotropin).ti,ab. |
| 37. | or/27–36 |
| 38. | 26 and 37 |
| 39. | randomized controlled trial.pt. |
| 40. | controlled clinical trial.pt. |
| 41. | randomi#ed.ti,ab. |
| 42. | placebo.ab. |
| 43. | randomly.ti,ab. |
| 44. | Clinical Trials as topic.sh. |
| 45. | trial.ti. |
| 46. | or/39–45 |
| 47. | Meta-Analysis/ |
| 48. | exp Meta-Analysis as Topic/ |
| 49. | (meta analy* or metanaly* or metaanaly* or meta regression).ti,ab. |
| 50. | ((systematic* or evidence*) adj3 (review* or overview*)).ti,ab. |
| 51. | (reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab. |
| 52. | (search strategy or search criteria or systematic search or study selection or data extraction).ab. |
| 53. | (search* adj4 literature).ab. |
| 54. | (medline or pubmed or cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or science citation index or bids or cancerlit).ab. |
| 55. | cochrane.jw. |
| 56. | ((multiple treatment* or indirect or mixed) adj2 comparison*).ti,ab. |
| 57. | or/47–56 |
| 58. | 38 and (46 or 57) |
Embase (Ovid) search terms
| 1. | exp thyroid disease/ |
| 2. | hyperthyroid*.ti,ab. |
| 3. | hypothyroid*.ti,ab. |
| 4. | thyrotoxicosis.ti,ab. |
| 5. | (thyroid adj3 (swell* or dysfunction* or enlarg* or nodule* or node* or disease* or condition* or disorder*)).ti,ab. |
| 6. | or/1–5 |
| 7. | letter.pt. or letter/ |
| 8. | note.pt. |
| 9. | editorial.pt. |
| 10. | case report/ or case study/ |
| 11. | (letter or comment*).ti. |
| 12. | or/7–11 |
| 13. | randomized controlled trial/ or random*.ti,ab. |
| 14. | 12 not 13 |
| 15. | animal/ not human/ |
| 16. | nonhuman/ |
| 17. | exp Animal Experiment/ |
| 18. | exp Experimental Animal/ |
| 19. | animal model/ |
| 20. | exp Rodent/ |
| 21. | (rat or rats or mouse or mice).ti. |
| 22. | or/14–21 |
| 23. | 6 not 22 |
| 24. | limit 23 to English language |
| 25. | ((iodine or selenium) adj2 supplement*).ti,ab. |
| 26. | (desiccated adj3 (thyroid or hormone* or extract or extracts)).ti,ab. |
| 27. | (thyroid adj2 (extract or extracts)).ti,ab. |
| 28. | (natural adj4 thyroid).ti,ab. |
| 29. | armour*.ti,ab. |
| 30. | *thyroxine/ or *levothyroxine/ or *liothyronine/ or *triiodothyronine/ |
| 31. | (thyroxine or levothyroxine or liothyronine or triiodothyronine or tri-iodothyronine).ti,ab. |
| 32. | (T3 or T4).ti,ab. |
| 33. | (TSH or thyroid stimulating hormone or thyrotropin).ti,ab. |
| 34. | *thyrotropin/ |
| 35. | or/25–34 |
| 36. | 24 and 35 |
| 37. | random*.ti,ab. |
| 38. | factorial*.ti,ab. |
| 39. | (crossover* or cross over*).ti,ab. |
| 40. | ((doubl* or singl*) adj blind*).ti,ab. |
| 41. | (assign* or allocat* or volunteer* or placebo*).ti,ab. |
| 42. | crossover procedure/ |
| 43. | single blind procedure/ |
| 44. | randomized controlled trial/ |
| 45. | double blind procedure/ |
| 46. | or/37–45 |
| 47. | systematic review/ |
| 48. | meta-analysis/ |
| 49. | (meta analy* or metanaly* or metaanaly* or meta regression).ti,ab. |
| 50. | ((systematic* or evidence*) adj3 (review* or overview*)).ti,ab. |
| 51. | (reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab. |
| 52. | (search strategy or search criteria or systematic search or study selection or data extraction).ab. |
| 53. | (search* adj4 literature).ab. |
| 54. | (medline or pubmed or cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or science citation index or bids or cancerlit).ab. |
| 55. | cochrane.jw. |
| 56. | ((multiple treatment* or indirect or mixed) adj2 comparison*).ti,ab. |
| 57. | or/47–56 |
| 58. | 36 and (46 or 57) |
Cochrane Library (Wiley) search terms
| #1. | MeSH descriptor: [Thyroid Diseases] explode all trees |
| #2. | hyperthyroid*:ti,ab |
| #3. | hypothyroid*:ti,ab |
| #4. | thyrotoxicosis:ti,ab |
| #5. | (thyroid near/3 (swell* or dysfunction* or enlarg* or nodule* or node* or disease* or condition* or disorder*)):ti,ab |
| #6. | (or #1–#5) |
| #7. | ((iodine or selenium) near/2 supplement*):ti,ab |
| #8. | (desiccated near/3 (thyroid or hormone* or extract or extracts)):ti,ab |
| #9. | (thyroid near/2 (extract or extracts)):ti,ab |
| #10. | (natural near/4 thyroid):ti,ab |
| #11. | (natural near/3 (extract or extracts)):ti,ab |
| #12. | armour*:ti,ab |
| #13. | (thyroxine or levothyroxine or liothyronine or triiodothyronine or tri-iodothyronine):ti,ab |
| #14. | MeSH descriptor: [Thyroxine] explode all trees |
| #15. | MeSH descriptor: [Triiodothyronine] explode all trees |
| #16. | (T3 or T4):ti,ab |
| #17. | (TSH or thyroid stimulating hormone or thyrotropin):ti,ab |
| #18. | (or #7–#17) |
| #19. | #6 and #18 |
B.2. Health Economics literature search strategy
Health economic evidence was identified by conducting a broad search relating to a thyroid disease population in NHS Economic Evaluation Database (NHS EED – this ceased to be updated after March 2015) and the Health Technology Assessment database (HTA) with no date restrictions. NHS EED and HTA databases are hosted by the Centre for Research and Dissemination (CRD). Additional searches were run on Medline and Embase for health economics, economic modelling and quality of life studies.
Table 7Database date parameters and filters used
| Database | Dates searched | Search filter used |
|---|---|---|
| Medline | 2014 – 07 January 2019 |
Exclusions Health economics studies Health economics modelling studies Quality of life studies |
| Embase | 2014 – 07 January 2019 |
Exclusions Health economics studies Health economics modelling studies Quality of life studies |
| Centre for Research and Dissemination (CRD) |
HTA - Inception – 07 January 2019 NHSEED - Inception to March 2015 | None |
Medline (Ovid) search terms
| 1. | exp thyroid diseases/ |
| 2. | hyperthyroid*.ti,ab. |
| 3. | hypothyroid*.ti,ab. |
| 4. | thyrotoxicosis.ti,ab. |
| 5. | (thyroid adj3 (swell* or dysfunction* or enlarg* or nodule* or node* or disease* or condition* or disorder*)).ti,ab. |
| 6. | or/1–5 |
| 7. | letter/ |
| 8. | editorial/ |
| 9. | news/ |
| 10. | exp historical article/ |
| 11. | Anecdotes as Topic/ |
| 12. | comment/ |
| 13. | case report/ |
| 14. | (letter or comment*).ti. |
| 15. | or/7–14 |
| 16. | randomized controlled trial/ or random*.ti,ab. |
| 17. | 15 not 16 |
| 18. | animals/ not humans/ |
| 19. | exp Animals, Laboratory/ |
| 20. | exp Animal Experimentation/ |
| 21. | exp Models, Animal/ |
| 22. | exp Rodentia/ |
| 23. | (rat or rats or mouse or mice).ti. |
| 24. | or/17–23 |
| 25. | 6 not 24 |
| 26. | limit 25 to English language |
| 27. | Economics/ |
| 28. | Value of life/ |
| 29. | exp “Costs and Cost Analysis”/ |
| 30. | exp Economics, Hospital/ |
| 31. | exp Economics, Medical/ |
| 32. | Economics, Nursing/ |
| 33. | Economics, Pharmaceutical/ |
| 34. | exp “Fees and Charges”/ |
| 35. | exp Budgets/ |
| 36. | budget*.ti,ab. |
| 37. | cost*.ti. |
| 38. | (economic* or pharmaco?economic*).ti. |
| 39. | (price* or pricing*).ti,ab. |
| 40. | (cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab. |
| 41. | (financ* or fee or fees).ti,ab. |
| 42. | (value adj2 (money or monetary)).ti,ab. |
| 43. | or/27–42 |
| 44. | exp models, economic/ |
| 45. | *Models, Theoretical/ |
| 46. | *Models, Organizational/ |
| 47. | markov chains/ |
| 48. | monte carlo method/ |
| 49. | exp Decision Theory/ |
| 50. | (markov* or monte carlo).ti,ab. |
| 51. | econom* model*.ti,ab. |
| 52. | (decision* adj2 (tree* or analy* or model*)).ti,ab. |
| 53. | or/44–52 |
| 54. | quality-adjusted life years/ |
| 55. | sickness impact profile/ |
| 56. | (quality adj2 (wellbeing or well being)).ti,ab. |
| 57. | sickness impact profile.ti,ab. |
| 58. | disability adjusted life.ti,ab. |
| 59. | (qal* or qtime* or qwb* or daly*).ti,ab. |
| 60. | (euroqol* or eq5d* or eq 5*).ti,ab. |
| 61. | (qol* or hql* or hqol* or h qol* or hrqol* or hr qol*).ti,ab. |
| 62. | (health utility* or utility score* or disutilit* or utility value*).ti,ab. |
| 63. | (hui or hui1 or hui2 or hui3).ti,ab. |
| 64. | (health* year* equivalent* or hye or hyes).ti,ab. |
| 65. | discrete choice*.ti,ab. |
| 66. | rosser.ti,ab. |
| 67. | (willingness to pay or time tradeoff or time trade off or tto or standard gamble*).ti,ab. |
| 68. | (sf36* or sf 36* or short form 36* or shortform 36* or shortform36*).ti,ab. |
| 69. | (sf20 or sf 20 or short form 20 or shortform 20 or shortform20).ti,ab. |
| 70. | (sf12* or sf 12* or short form 12* or shortform 12* or shortform12*).ti,ab. |
| 71. | (sf8* or sf 8* or short form 8* or shortform 8* or shortform8*).ti,ab. |
| 72. | (sf6* or sf 6* or short form 6* or shortform 6* or shortform6*).ti,ab. |
| 73. | or/54–72 |
| 74. | 26 and (43 or 53 or 73) |
Embase (Ovid) search terms
| 1. | exp thyroid diseases/ |
| 2. | hyperthyroid*.ti,ab. |
| 3. | hypothyroid*.ti,ab. |
| 4. | thyrotoxicosis*.ti,ab. |
| 5. | (thyroid adj3 (swell* or dysfunction* or enlarg* or nodule* or node* or disease* or condition* or disorder*)).ti,ab. |
| 6. | or/1–5 |
| 7. | letter.pt. or letter/ |
| 8. | note.pt. |
| 9. | editorial.pt. |
| 10. | case report/ or case study/ |
| 11. | (letter or comment*).ti. |
| 12. | or/7–11 |
| 13. | randomized controlled trial/ or random*.ti,ab. |
| 14. | 12 not 13 |
| 15. | animal/ not human/ |
| 16. | nonhuman/ |
| 17. | exp Animal Experiment/ |
| 18. | exp Experimental Animal/ |
| 19. | animal model/ |
| 20. | exp Rodent/ |
| 21. | (rat or rats or mouse or mice).ti. |
| 22. | or/14–21 |
| 23. | 6 not 22 |
| 24. | limit 23 to English language |
| 25. | health economics/ |
| 26. | exp economic evaluation/ |
| 27. | exp health care cost/ |
| 28. | exp fee/ |
| 29. | budget/ |
| 30. | funding/ |
| 31. | budget*.ti,ab. |
| 32. | cost*.ti. |
| 33. | (economic* or pharmaco?economic*).ti. |
| 34. | (price* or pricing*).ti,ab. |
| 35. | (cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab. |
| 36. | (financ* or fee or fees).ti,ab. |
| 37. | (value adj2 (money or monetary)).ti,ab. |
| 38. | or/25–37 |
| 39. | statistical model/ |
| 40. | exp economic aspect/ |
| 41. | 39 and 40 |
| 42. | *theoretical model/ |
| 43. | *nonbiological model/ |
| 44. | stochastic model/ |
| 45. | decision theory/ |
| 46. | decision tree/ |
| 47. | monte carlo method/ |
| 48. | (markov* or monte carlo).ti,ab. |
| 49. | econom* model*.ti,ab. |
| 50. | (decision* adj2 (tree* or analy* or model*)).ti,ab. |
| 51. | or/41–50 |
| 52. | quality adjusted life year/ |
| 53. | “quality of life index”/ |
| 54. | short form 12/ or short form 20/ or short form 36/ or short form 8/ |
| 55. | sickness impact profile/ |
| 56. | (quality adj2 (wellbeing or well being)).ti,ab. |
| 57. | sickness impact profile.ti,ab. |
| 58. | disability adjusted life.ti,ab. |
| 59. | (qal* or qtime* or qwb* or daly*).ti,ab. |
| 60. | (euroqol* or eq5d* or eq 5*).ti,ab. |
| 61. | (qol* or hql* or hqol* or h qol* or hrqol* or hr qol*).ti,ab. |
| 62. | (health utility* or utility score* or disutilit* or utility value*).ti,ab. |
| 63. | (hui or hui1 or hui2 or hui3).ti,ab. |
| 64. | (health* year* equivalent* or hye or hyes).ti,ab. |
| 65. | discrete choice*.ti,ab. |
| 66. | rosser.ti,ab. |
| 67. | (willingness to pay or time tradeoff or time trade off or tto or standard gamble*).ti,ab. |
| 68. | (sf36* or sf 36* or short form 36* or shortform 36* or shortform36*).ti,ab. |
| 69. | (sf20 or sf 20 or short form 20 or shortform 20 or shortform20).ti,ab. |
| 70. | (sf12* or sf 12* or short form 12* or shortform 12* or shortform12*).ti,ab. |
| 71. | (sf8* or sf 8* or short form 8* or shortform 8* or shortform8*).ti,ab. |
| 72. | (sf6* or sf 6* or short form 6* or shortform 6* or shortform6*).ti,ab. |
| 73. | or/52–72 |
| 74. | 24 and (38 or 51 or 73) |
NHS EED and HTA (CRD) search terms
| #1. | MeSH DESCRIPTOR Thyroid Diseases EXPLODE ALL TREES |
| #2. | hyperthyroid* |
| #3. | hypothyroid* |
| #4. | thyrotoxicosis* |
| #5. | (thyroid adj3 (swell* or dysfunction* or enlarg* or nodule* or node* or disease* or condition* or disorder*)) |
| #6. | #1 OR #2 OR #3 OR #4 or #5 |
Appendix C. Clinical evidence selection
Figure 1Flow chart of clinical study selection for the review of management of subclinical hypothyroidism
Appendix D. Clinical evidence tables
Download PDF (1.5M)
Appendix E. Forest plots
E.1. Subclinical hypothyroidism – T4 vs placebo in Adults
.&p=BOOKS&id=577228_ch7appef1.jpg "Click on image to zoom")
Figure 3Quality of life: hypothyroid dependent (T-QoL, −3 to 1, high = good, at 12 months)
.&p=BOOKS&id=577228_ch7appef2.jpg "Click on image to zoom")
Figure 4Quality of life: general health (SF-36, 0–100, high=good, at 6 months)
.&p=BOOKS&id=577228_ch7appef3.jpg "Click on image to zoom")
Figure 5Quality of life: physical functioning (SF-36, 0–100, high=good, at 6 months)
.&p=BOOKS&id=577228_ch7appef4.jpg "Click on image to zoom")
Figure 6Quality of life: role-physical (SF-36, 0–100, high=good, at 6 months)
.&p=BOOKS&id=577228_ch7appef5.jpg "Click on image to zoom")
Figure 7Quality of life: social functioning (SF-36, 0–100, high=good, at 6 months)
.&p=BOOKS&id=577228_ch7appef6.jpg "Click on image to zoom")
Figure 8Quality of life: role-emotional (SF-36, 0–100, high=good, at 6 months)
.&p=BOOKS&id=577228_ch7appef7.jpg "Click on image to zoom")
Figure 9Quality of life: mental health (SF-36, 0–100, high=good, at 6 months)
.&p=BOOKS&id=577228_ch7appef8.jpg "Click on image to zoom")
Figure 10Quality of life: vitality (SF-36, 0–100, high=good, at 6 months)
.&p=BOOKS&id=577228_ch7appef9.jpg "Click on image to zoom")
Figure 11Quality of life: bodily pain (SF-36, 0–100, high=good, at 6 months)
.&p=BOOKS&id=577228_ch7appef10.jpg "Click on image to zoom")
Figure 12Depression (BDI, 0–63, high=poor, at 3–6 months)
.&p=BOOKS&id=577228_ch7appef11.jpg "Click on image to zoom")
Figure 13Hypothyroid symptoms (Multiple scales, high=poor, at 6–12 months)
.&p=BOOKS&id=577228_ch7appef12.jpg "Click on image to zoom")
Figure 14TSH suppression (> reference, at 3 months)
E.2. Subclinical hypothyroidism - T4 vs placebo for older adults
.&p=BOOKS&id=577228_ch7appef13.jpg "Click on image to zoom")
Figure 15Quality of life (EQ-5D, −0.59–1, high=good, at 12 months)
.&p=BOOKS&id=577228_ch7appef14.jpg "Click on image to zoom")
Figure 16Quality of life (EQ VAS, 0–100, high=good, at 12 months)
.&p=BOOKS&id=577228_ch7appef15.jpg "Click on image to zoom")
Figure 17Hypothyroid symptoms (ThyPRO, 0–100, high=poor, at 12 months)
.&p=BOOKS&id=577228_ch7appef16.jpg "Click on image to zoom")
Figure 18Hyperthyroid symptoms (Thy-PRO, 0–100, high= poor, at 12 months)
Appendix F. GRADE tables
Table 8Clinical evidence profile: T4 versus placebo in adults
| Quality assessment | No of patients | Effect | Quality | Importance | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | T4 | Placebo | Relative (95% CI) | Absolute | ||
| QoL: Hypothyroid-dependent (follow-up 12 months; measured with: T-QoL; range of scores: −3–1; Better indicated by higher values) | ||||||||||||
| 1 | randomised trials | serious2 | no serious inconsistency | no serious indirectness | no serious imprecision | none | 100 | 100 | - | MD 0.1 higher (0.16 lower to 0.36 higher) |
⨁⨁⨁◯ MODERATE | CRITICAL |
| QoL: General health (follow-up 6 months; measured with: SF-36; range of scores: 0–100; Better indicated by higher values) | ||||||||||||
| 1 | randomised trials | serious2 | no serious inconsistency | no serious indirectness | very serious1 | none | 25 | 32 | - | MD 0.9 lower (9.08 lower to 7.28 higher) |
⨁◯◯◯ VERY LOW | CRITICAL |
| QoL: Physical functioning (follow-up 6 months; measured with: SF-36; range of scores: 0–100; Better indicated by higher values) | ||||||||||||
| 1 | randomised trials | serious2 | no serious inconsistency | no serious indirectness | very serious1 | none | 25 | 32 | - | MD 1.8 higher (8.27 lower to 11.87 higher) |
⨁◯◯◯ VERY LOW | CRITICAL |
| QoL: Role-physical (follow-up 6 months; measured with: SF-36; range of scores: 0–100; Better indicated by higher values) | ||||||||||||
| 1 | randomised trials | serious2 | no serious inconsistency | no serious indirectness | no serious imprecision1 | none | 25 | 32 | - | MD 30.1 higher (7.86 to 52.34 higher) |
⨁⨁⨁◯ MODERATE | CRITICAL |
| QoL: Social functioning (follow-up 6 months; measured with: SF-36; range of scores: 0–100; Better indicated by higher values) | ||||||||||||
| 1 | randomised trials | serious2 | no serious inconsistency | no serious indirectness | very serious1 | none | 25 | 32 | - | MD 1 higher (13.93 lower to 15.93 higher) |
⨁◯◯◯ VERY LOW | CRITICAL |
| QoL: Role-emotional (follow-up 6 months; measured with: SF-36; range of scores: 0–100; Better indicated by higher values) | ||||||||||||
| 1 | randomised trials | serious2 | no serious inconsistency | no serious indirectness | serious1 | none | 25 | 32 | - | MD 25.1 higher (1.72 to 48.48 higher) |
⨁⨁◯◯ LOW | CRITICAL |
| QoL: Mental health (follow-up 6 months; measured with: SF-36; range of scores: 0–100; Better indicated by higher values) | ||||||||||||
| 1 | randomised trials | serious2 | no serious inconsistency | no serious indirectness | very serious1 | none | 25 | 32 | - | MD 5.4 lower (18.85 lower to 8.05 higher) |
⨁◯◯◯ VERY LOW | CRITICAL |
| QoL: Vitality (follow-up 3–6 months; measured with: SF-36; range of scores: 0–100; Better indicated by higher values) | ||||||||||||
| 1 | randomised trials | serious2 | no serious inconsistency | no serious indirectness | very serious1 | none | 25 | 32 | - | MD 2.5 lower (14.08 lower to 9.08 higher) |
⨁◯◯◯ VERY LOW | CRITICAL |
| QoL: Bodily pain (follow-up 6 months; measured with: SF-36; range of scores: 0–100; Better indicated by higher values) | ||||||||||||
| 1 | randomised trials | serious2 | no serious inconsistency | no serious indirectness | no serious imprecision1 | none | 25 | 32 | - | MD 24.3 higher (15.95 to 32.65 higher) |
⨁⨁⨁◯ MODERATE | CRITICAL |
| Depression (follow-up 3–6 months; measured with: BDI (final values & change scores); range of scores: 0–63; Better indicated by lower values) | ||||||||||||
| 2 | randomised trials | serious2 | no serious inconsistency | no serious indirectness | no serious imprecision | none | 55 | 62 | - | MD 0.12 lower (2.6 lower to 2.36 higher) |
⨁⨁⨁◯ MODERATE | IMPORTANT |
| Hypothyroid symptoms (follow-up 6–12 months; measured with: Zulewski, signs and symptoms of hypothyroidism; Multiple scales; Better indicated by lower values) | ||||||||||||
| 2 | randomised trials | no serious risk of bias | no serious inconsistency | no serious indirectness | no serious imprecision | none | 51 | 47 | - | SMD 0.03 lower (0.43 lower to 0.37 higher) |
⨁⨁⨁⨁ HIGH | IMPORTANT |
| TSH suppression (<0.4 mlU/L) (follow-up 3 months; assessed with: cases) | ||||||||||||
| 2 | randomised trials | serious2 | no serious inconsistency | no serious indirectness | very serious1 | none | 10/130 (7.7%) | 0% | OR 8.12 (2.28 to 28.89) | 80 more per 1000 (from 0.03 more to 0.13 more)3 |
⨁◯◯◯ VERY LOW | IMPORTANT |
- 1
Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
- 2
Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs
- 3
zero events in both arms of one study and one arm of one study
Table 9Clinical evidence profile: T4 versus placebo in older adults
| Quality assessment | No of patients | Effect | Quality | Importance | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | T4 | Placebo in older adults | Relative (95% CI) | Absolute | ||
| QoL (follow-up 12 months; measured with: EQ-5D; range of scores: −0.59–1; Better indicated by higher values) | ||||||||||||
| 1 | randomised trials | no serious risk of bias | no serious inconsistency | no serious indirectness | serious1 | none | 318 | 320 | - | MD 0.02 lower (0.05 lower to 0.01 higher) |
⨁⨁⨁◯ MODERATE | CRITICAL |
| QoL (follow-up 12 months; measured with: EQ VAS; range of scores: 0–100; Better indicated by higher values) | ||||||||||||
| 1 | randomised trials | no serious risk of bias | no serious inconsistency | no serious indirectness | no serious imprecision | none | 318 | 320 | - | MD 0.1 lower (2.38 lower to 2.18 higher) |
⨁⨁⨁⨁ HIGH | CRITICAL |
| Hypothyroid symptoms (follow-up 12 months; measured with: ThyPRO-hypothyroidism; range of scores: 0–100; Better indicated by lower values) | ||||||||||||
| 1 | randomised trials | no serious risk of bias | no serious inconsistency | no serious indirectness | no serious imprecision | none | 318 | 320 | - | MD 0.1 lower (2.77 lower to 2.57 higher) |
⨁⨁⨁⨁ HIGH | IMPORTANT |
| Hypethyroid symptoms (follow-up 12 months; measured with: ThyPRO hyperthyroidism; range of scores: 0–100; Better indicated by lower values) | ||||||||||||
| 1 | randomised trials | no serious risk of bias | no serious inconsistency | no serious indirectness | no serious imprecision | none | 318 | 320 | - | MD 0.2 higher (1.52 lower to 1.92 higher) |
⨁⨁⨁⨁ HIGH | IMPORTANT |
- 1
Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs
Appendix G. Health economic evidence selection
Figure 2Flow chart of health economic study selection for the guideline
* Non-relevant population, intervention, comparison, design or setting; non-English language
TFT; thyroid function test, FNA; fine-needle aspiration, US; ultrasound, RAI; radioactive iodine, ATDs; antithyroid drugs, Mang; management, SCH; Subclinical hypothyroidism, SCT; Subclinical thyrotoxicosis.
Appendix H. Health economic evidence tables
None
Appendix I. Health economic analysis
None
Appendix J. Excluded studies
J.1. Excluded clinical studies
Table 10Studies excluded from the clinical review
| Study | Exclusion reason |
|---|---|
| Abreu 20171 | References checked |
| Aghili 20122 | No usable outcomes |
| Akintola 20153 | Systematic review-references checked |
| Angermayr 20044 | Not review population |
| Appelhof 20055 | Not review population |
| Cabral 20117 | No usable outcomes |
| Caraccio 20028 | No usable outcomes |
| Caraccio 20059 | No usable outcomes |
| Cassio 200310 | Less than minimum duration |
| Cerbone 201611 | Inappropriate comparison. Incorrect interventions. No usable outcomes. inappropriate control group |
| Cooper 198412 | No usable outcomes matching protocol |
| Fadeyev 200613 | no usable outcomes matching protocol |
| Feller 201814 | SR, references checked |
| Ineck 200315 | SR, references checked |
| Iqbal 200616 | No usable outcomes |
| Jorde 200618 | No usable outcomes |
| Koroglu 201220 | No usable outcomes |
| Li 201621 | References checked |
| Mainenti 200922 | Incorrect interventions. Inappropriate comparison. No placebo |
| Martins 201123 | No usable outcomes matching protocol |
| Monzani 200126 | No usable outcomes |
| Monzani 200425 | No usable outcome matching protocol |
| Nagasaki 200927 | No usable outcomes |
| Ng 200930 | Not review population. References checked |
| Nystrom 198831 | No usable outcomes matching protocol |
| Parle 201032 | No usable outcomes |
| Pollock 200133 | Not review population |
| Ross 199336 | No usable outcomes matching protocol. No control group |
| Ruggeri 201737 | References checked |
| Segna 201738 | Systematic review: study designs inappropriate. Inappropriate comparison. Incorrect interventions |
| Shatynska-mytsyk 201639 | Non-randomised controlled study |
| Sun 201741 | Systematic review: study designs inappropriate. References checked |
| Taylor 201442 | Supplementation study in iodine deficient country. References checked |
| Teixeira 200843 | no usable outcomes matching protocol |
| Valizadeh 200944 | Not review population |
| Wasniewska 201246 | Incorrect interventions. no usable outcomes matching protocol |
| Yazici 200447 | No usable outcomes |
| Yetmis 201148 | Not in English |
| Zhao 201649 | No usable outcomes |
| Zhao 201750 | References checked |
| Zhu 201251 | Not in English |
J.2. Excluded health economic studies
None
Appendix K. Research recommendations
K.1. Research question: What is the clinical and cost effectiveness of levothyroxine for people under 65 with symptomatic subclinical hypothyroidism?
Why this is important:
Subclinical hypothyroidism (SCH) is a common biochemical abnormality that affects around 1% of people less than 70 years of age, rising to 6% in people in 80s. It is frequently transient and most people are asymptomatic. Large observational population surveys show that SCH is associated with increased vascular events, heart failure and mortality in younger individuals (50–70 age range). This may be because of a combination of dyslipidaemia caused by mild hypothyroidism and direct deficiency of thyroid hormone action on the myocardium. No randomised study of sufficient follow-up has been carried out that addressed the issue of long-term health outcomes in SCH. One high profile, randomised controlled trial studying the effect of sub therapeutic doses of levothyroxine (25 and 50mcg/d) in a largely asymptomatic group of older adults with SCH, on health-related QoL and symptoms at 12 months showed no clinically important benefit or harm from a low-dose of levothyroxine.
What remains unknown is whether symptomatic individuals with SCH aged <65 years could benefit from regular ‘replacement’ doses of levothyroxine both in terms of improvement in symptoms/QoL and of long-term cardiovascular events. Given the prevalence of SCH in women, it could be a major and entirely reversible cardiac risk factor but this idea remains essentially untested.
Criteria for selecting high-priority research recommendations
| PICO question |
Population: Adults 50–70 years of age with persistent symptomatic SCH, defined as TSH >5.0mIU/l, normal FT4. Intervention(s): Levothyroxine ~1.0mcg/Kg/day; short duration-(?1yr) for QoL, 5yrs for major adverse cardiac events (MACE). Comparison: Placebo Outcome(s): symptoms, QoL (ThyPRO), MACE |
|---|---|
| Importance to patients or the population | A clinical trial would determine the effectiveness of treatment with therapeutic doses of levothyroxine for individuals aged 50–70 years. This could lead to improved treatment outcomes while minimising long-term cardiovascular risks and mortality at a very small cost. |
| Relevance to NICE guidance | This will address the lack of sufficient evidence to guide the management of symptomatic people with SCH using levothyroxine. |
| Relevance to the NHS | Evidence of the effect of levothyroxine in people with SCH younger than 65 / 50–70 years of age would ensure clinically and cost effective treatment for those people. |
| National priorities | There is a potential to improve CV event rates and mortality, which are national priorities |
| Current evidence base | Current evidence-base is limited to a single high profile study of limited follow-up which used a low dose of levothyroxine and looked for improvement in symptoms in a largely asymptomatic population |
| Equality | This disease is over-represented in women |
| Study design | Randomised, double blind placebo-controlled study of levothyroxine ~1.0 mcg/kg/d in people aged 50–70 years with persistent SCH for 3 months, 5 years intervention with MACE as the primary outcome |
| Feasibility | This would be an expensive study but a national ‘randomisation, mail-out tablets for 5yrs, body count’ approach through NHSCR would be feasible |
| Other comments | Our experience is that GPs frequently do measure TFTs and the current evidence-base leads to uncertainty and heterogeneous practice. This was suggested to NIHR back in ~2009 when BTA was asked for research suggestions but a multicentre application led by Cardiff was not funded largely due to costs >£6M |
| Importance | High. The guidelines are unable to provide clear recommendations for levothyroxine treatment for symptomatic people with SCH due to a lack of sufficient evidence. A well-executed randomised study could inform future updates. |
K.2. Research question: What is the clinical and cost effectiveness of selenium for people with subclinical hypothyroidism?
Why this is important:
Subclinical hypothyroidism (SCH) is a biochemical abnormality that affects around 1% of people less than 70 years of age and 6% of people at 80 years. It is frequently transient and most people are asymptomatic. Large observational population surveys show that SCH is associated with increased vascular events, heart failure and mortality in individuals aged 50–70 years. This may be because of a combination of dyslipidaemia caused by mild hypothyroidism and direct deficiency of thyroid hormone action on the myocardium. SCH has furthermore been associated with increased all-cause and cardiovascular mortality.
Public interest regarding selenium supplementation for SCH was expressed at the scoping stage of this guideline. The metabolism of thyroid hormones isinfluenced by micronutrients such as selenium. Existing studies have examined the effect of micronutrient supplementation on the concentration of thyroid hormones, and observational evidence suggests a positive association. However, data from randomized controlled trials have failed to confirm this relationship.
Within the development of the present guideline, no evidence supporting selenium as a treatment modality for SCH was identified. There remains uncertainty regarding the efficacy and effectiveness of selenium supplementation as a treatment, although public interest remains high. There is therefore a need for a high quality trial to examine its clinical and cost effectiveness for the treatment of SCH.
Criteria for selecting high-priority research recommendations
| PICO question |
Population: People with subclinical hypothyroidism Intervention:selenium Comparison: treatment with levothyroxine/ no treatment (placebo) Outcome(s): mortality, quality of life, adverse events (including cardiovascular, osteoporosis, impaired cognitive function) depression, hypothyroid/hyperthyroid symptoms, growth, TSH suppression |
|---|---|
| Importance to patients or the population | If selenium provides clinically important benefits for people with SCH at a reasonable cost then it may be an important therapeutic modality to enhance clinical outcomes in this patient group that remains largely untreated. |
| Relevance to NICE guidance | This will address the lack of evidence to guide the management of people with SCH using selenium and guide future guideline development. |
| Relevance to the NHS | Evidence of the clinical and cost effectiveness of selenium for SCH would support its delivery as medicine for SCH ensuring the effective treatment of people with this condition. |
| National priorities | Considering the association of SCH with increased CV events, heart failure and mortality, identifying the effectiveness of the examined treatments provides the potential to improve CV event rates and mortality which are national priorities. |
| Current evidence base | There are currently no high quality studies supporting the effectiveness of selenium in treating people with SCH to support the development of recommendations for their use. |
| Equality | There are no equality issues |
| Study design | Randomised, double blind placebo-controlled trial of selenium supplementation (3 months minimum duration) with long-term follow-up in people with SCH and a corresponding health economic analysis. |
| Feasibility | High interest of patients with SCH in the effectiveness of selenium as treatment is likely to ensure the identification of an adequate sample to enable the study. |
| Other comments | Selenium is widely available on the market in the form of dietary supplements and can be obtained without prescription. |
| Importance | Low. The research is of interest to patients with SCH and will target the existing lack of evidence for selenium for the treatment of SCH. However existing evidence suggests treatment of SCH in general, with conventional treatments like levothyroxine, does not result in clinically important benefits for most people. |
K.3. Research question: What is the clinical and cost effectiveness of iodine for people with subclinical hypothyroidism?
Why this is important:
Subclinical hypothyroidism (SCH) is a biochemical abnormality that affects around 1% of people less than 70 years of age and 6% of people at 80 years. It is frequently transient and most people are asymptomatic. Large observational population surveys show that SCH is associated with increased vascular events, heart failure and mortality in individuals aged 50–70 years. This may be because of a combination of dyslipidaemia caused by mild hypothyroidism and direct deficiency of thyroid hormone action on the myocardium. SCH has furthermore been associated with increased all-cause and cardiovascular mortality.
Public interest regarding iodine supplementation for SCH was expressed at the scoping stage of this guideline. The metabolism of thyroid hormones requires iodine as key component. Existing studies have examined the effect of iodine status and the concentration of thyroid hormones, and observational evidence suggests a positive association. However, data from randomized controlled trials have failed to confirm this relationship.
Within the development of the present guideline, no evidence supporting iodine as a treatment modality for SCH was identified. There remains uncertainty regarding the efficacy and effectiveness of iodine supplementation as treatment, although public interest remains high. There is therefore a need for a high quality trial to examine its clinical and cost effectiveness for the treatment of SCH.
Criteria for selecting high-priority research recommendations
| PICO question |
Population: People with subclinical hypothyroidism Intervention: iodine Comparison: treatment with levothyroxine/ no treatment (placebo) Outcome(s): mortality, quality of life, adverse events (including cardiovascular, osteoporosis, impaired cognitive function) depression, hypothyroid/hyperthyroid symptoms, growth, TSH suppression |
|---|---|
| Importance to patients or the population | If iodine provides clinically important benefits for people with SCH at a reasonable cost then it may be an important therapeutic modality to enhance clinical outcomes in this patient group that remains largely untreated. |
| Relevance to NICE guidance | This will address the lack of evidence to guide the management of people with SCH using iodine and guide future guideline development. |
| Relevance to the NHS | Evidence of the clinical and cost effectiveness of iodine for SCH would support its delivery as medicine for SCH ensuring the effective treatment of people with this condition. |
| National priorities | Considering the association of SCH with increased CV events, heart failure and mortality, identifying the effectiveness of the examined treatment provides the potential to improve CV event rates and mortality which are national priorities. |
| Current evidence base | There are currently no high quality studies supporting the effectiveness of iodine in treating people with SCH to support the development of recommendations for their use. |
| Equality | There are no equality issues |
| Study design | Randomised, double blind placebo-controlled trial of iodine supplementation (3 months minimum duration) with long-term follow-up in people with SCH and a corresponding health economic analysis. |
| Feasibility | High interest of patients with SCH in the effectiveness of iodine as treatment is likely to ensure the identification of an adequate sample to enable the study. |
| Other comments | Iodine is widely available on the market in the form of dietary supplements and can be obtained without prescription. |
| Importance | Low. The research is of interest to patients with SCH and will target the existing lack of evidence for iodine for the treatment of SCH. However existing evidence suggests treatment of SCH in general, with conventional treatments like levothyroxine, does not result in clinically important benefits for most people. |
Tables
Table 1PICO characteristics of review question
| Population | People diagnosed with subclinical hypothyroidism (TSH greater than upper limit of context specific reference range, T3/T4 within reference range) |
|---|---|
| Interventions |
T3 T4-initiation at high dose T4-initiation via gradual titration Combination of T3 & T4 Natural thyroid extract (mammalian only) Iodine supplementation Selenium supplementation Placebo |
| Comparisons | Any above vs any other, in isolation or combination |
| Outcomes | Critical
|
| Study design |
|
Table 2Summary of studies included in the evidence review
| Study | Intervention and comparison | Population | Outcomes | Comments |
|---|---|---|---|---|
| Kong 200219 |
T4: 50–100 µg daily (depending on TSH >5 µU/mL), n= 23 Placebo: ascorbic acid, 5 mg daily, n=17 |
Women (T4 mean age 53 SD 3, placebo mean age 45, SD 4) TSH 5–10 µU/mL, T4 0.8–16ng/dL; baseline TSH (µU/mL): mean (SD) T4 8 (1.5); Placebo 7.3 (1.6) Symptom status: All except for two patients had self-reported symptoms suggestive of hypothyroidism; reported to have mild subclinical hypothyroidism Treatment naïve UK |
Symptom scores 6 months |
80 % autoimmune thyroiditis Parallel design Post-treatment TSH mean (SD) (µU/mL): T4 −4.6 (2.3); placebo - 1.7 (2) |
| Meier 2001 24 |
T4: 25, 50, 75, 100 or 125 µg daily, adapted every 6 weeks to achieve euthyroid TSH (0.14.0 mlU / liter), mean dose at end of study: 85.5 SD 4.3, n=31 Placebo: similar dose and adjustments, n=32 |
Women (T4 mean age 57.1 SD 10.34, placebo mean age 57.1 SD 10.91) TSH > 5mlU/L, exaggerated TSH response of more than 35 mlU/L after oral TRH stimulation; baseline TSH range 5.0–50 mlU/L, mean (SD) TSH (mlU/L): T4 12.8 (7.79); Placebo 10.7 (5.09) Symptom status: not reported Treatment naive Switzerland |
Symptom scores 12 months |
50% autoimmune thyroiditis, 33% RAI or SUR for Graves’ disease Parallel design TSH reference range 0.1–4.0 mlU/L Post treatment TSH mean (SD) (mlU/liter): T4 3.1 (1.67); Placebo:9.9 (3.94) |
| Najafi 2015 28 |
T4: 100 µg daily, n=30 Placebo, n=30 |
Adults (mean age: 34, SD: 10) 85% female TSH > 4.5 mlU/L, normal FT4 (0.8–2 ng/dl), positive anti-TPO-Ab; baseline TSH (mlU/L) mean (SD): T4 8.29 (4.9) Placebo 8.12 (3.12) Symptom status: symptomatic (most prevalent symptoms: weigh gain, fatigue, muscle cramp, irregular menstruation, limb numbness; no significant improvement post treatment) Treatment naïve Iran |
Depression TSH suppression 3 months |
Parallel design Post treatment TSH mean (SD) mlU/L: T4 2.01 (1.34); Placebo 7.82 (5.17) |
| Razvi 200734 |
T4: 100 µg daily, n=100 Placebo, n=100 |
Adults (mean age: 53.8, SD: 12) 81% female TSH> 4mlU/L, FT4 0.7–1.9 ng/dl; baseline TSH (mlU/L) median (range): 5.3 (3.7–15.8); T4 first 5.4 (3.8–15.8); Placebo first 5.3 (3.7–13.9) Symptom status: not reported Treatment naïve United Kingdom |
Hypothyroid-dependent quality of life TSH suppression (<0.4 mlU/L) 3 months |
51% Autoimmune thyroiditis Cross-over design TSH reference range 0.4–4.0 mlU/L Post treatment TSH median (range) mlU/liter : T4 0.5 (0.01–12); Placebo 5.2 (0.9–63.4) |
| Reuters 2012 35 |
T4: 25 mcg, 50 mcg or 75 mcg depending on stratification by TSH levels (adjusted at 2 months), n=35 Placebo: dose adjustment by TSH levels, n=36 |
Adults (mean age: 50.01, SD:10.89) TSH > 4 µU/mL, normal FT4 (0.9–1.8 ng/dL); baseline TSH (µU/mL) mean (SD) : T4 7.3 (2.3); Placebo 7.6 (2.7) No information provided on previous treatment Symptom status not reported 87.3% female Brazil |
Quality of life Depression 6 months |
68 % Autoimmune thyroiditis Parallel design TSH Reference range 0.4–4.0 mlU/L Post-treatment TSH not reported. |
| Stott 2017 40 |
T4: 50 µg daily (or 25 if body weight <50 kg or known coronary heart disease), adjusted according to TSH (0.40 - 4.59 mlU/L), n=368 Placebo: with mock dose adjustments, n=369 |
Older adults (mean age: 74.4, SD: 6.3) 53.7% female TSH 4.60 to 19.99 mlU/L, FT4 within reference range; baseline TSH (mlU/L) mean (SD) overall 6.40 (2.01), T4 6.41 (2.01), Placebo 6.38 (2.01) Symptom status: 27% asymptomatic (based on hypothyroid symptom scale) Mean baseline hypothyroid symptoms score: T4 17.5 (18.8); Placebo 16.9 (17.9); Mean baseline tiredness score: T4 25.9 (20.6); Placebo 25.5 (20.3) Treatment naïve United Kingdom, Netherlands, Switzerland |
Health related quality of life Symptom scores 12 months |
Multicentre Parallel design Post treatment TSH mean (SD) (mlU/liter): T4 3.63 (2.11); Placebo 5.48 (2.48) TSH at extended follow up visit mean (SD) (mlU/liter); T4 3.47 (2.08); Placebo 5.28 (2.50) |
Table 3Clinical evidence summary: T4 vs Placebo in adults
| Outcomes | No of Participants (studies) Follow up | Quality of the evidence (GRADE) | Relative effect (95% CI) | Anticipated absolute effects | |
|---|---|---|---|---|---|
| Risk with Placebo | Risk difference with T4 (95% CI) | ||||
|
QoL: Hypothyroid-dependent T-QoL. Scale from: −3 to 1. Better indicated by higher values. |
100 (1 study) 12 months |
⊕⊕⊕⊝ MODERATE2 due to risk of bias |
The mean qol: hypothyroid-dependent in the control groups was −1.2 |
The mean qol: hypothyroid-dependent in the intervention groups was 0.1 higher (0.16 lower to 0.36 higher) | |
|
QoL: General health SF-36. Scale from: 0 to 100. Better indicated by higher values. |
57 (1 study) 6 months |
⊕⊝⊝⊝ due to risk of bias, imprecision |
The mean qol: general health in the control groups was 7.4 |
The mean qol: general health in the intervention groups was 0.9 lower (9.08 lower to 7.28 higher) | |
|
QoL: Physical functioning SF-36. Scale from: 0 to 100. Better indicated by higher values. |
57 (1 study) 6 months |
⊕⊝⊝⊝ due to risk of bias, imprecision |
The mean qol: physical functioning in the control groups was 1.9 |
The mean qol: physical functioning in the intervention groups was 1.8 higher (8.27 lower to 11.87 higher) | |
|
QoL: Role-physical SF-36. Scale from: 0 to 100. Better indicated by higher values. |
57 (1 study) 6 months |
⊕⊕⊕⊝ MODERATE1, due to risk of bias |
The mean qol: role-physical in the control groups was −8 |
The mean qol: role-physical in the intervention groups was 30.1 higher (7.86 to 52.34 higher) | |
|
QoL: Social functioning SF-36. Scale from: 0 to 100. Better indicated by higher values. |
57 (1 study) 6 months |
⊕⊝⊝⊝ due to risk of bias, imprecision |
The mean qol: social functioning in the control groups was 0.3 |
The mean qol: social functioning in the intervention groups was 1 higher (13.93 lower to 15.93 higher) | |
|
QoL: Role-emotional SF-36. Scale from: 0 to 100. Better indicated by higher values. |
57 (1 study) 6 months |
⊕⊕⊝⊝ due to risk of bias, imprecision |
The mean qol: role-emotional in the control groups was 2.6 |
The mean qol: role-emotional in the intervention groups was 25.1 higher (1.72 to 48.48 higher) | |
|
QoL: Mental health SF-36. Scale from: 0 to 100. Better indicated by higher values. |
57 (1 study) 6 months |
⊕⊝⊝⊝ due to risk of bias, imprecision |
The mean qol: mental health in the control groups was 5.6 |
The mean qol: mental health in the intervention groups was 5.4 lower (18.85 lower to 8.05 higher) | |
|
QoL: Vitality SF-36. Scale from: 0 to 100. Better indicated by higher values. |
57 (1 study) 6 months |
⊕⊝⊝⊝ due to risk of bias, imprecision |
The mean qol: vitality in the control groups was 0.2 |
The mean qol: vitality in the intervention groups was 2.5 lower (14.08 lower to 9.08 higher) | |
|
QoL: Bodily pain SF-36. Scale from: 0 to 100. Better indicated by higher values. |
57 (1 study) 6 months |
⊕⊕⊕⊝ due to risk of bias |
The mean qol: bodily pain in the control groups was −4.6 |
The mean qol: bodily pain in the intervention groups was 24.3 higher (15.95 to 32.65 higher) | |
|
Depression BDI (final values & change scores). Scale from: 0 to 63. Better indicated by lower values. |
117 (2 studies) 3–6 months |
⊕⊕⊕⊝ MODERATE2 due to risk of bias |
The mean depression in the control groups was 4.88 |
The mean depression in the intervention groups was 0.12 lower (2.6 lower to 2.36 higher) | |
|
Hypothyroid symptoms Zulewski, other sign and symptom scale. Multiple scales. Better indicated by lower values. |
98 (2 studies) 6–12 months |
⊕⊕⊕⊕ HIGH |
The mean hypothyroid symptoms in the control groups was 2.05 |
The mean hypothyroid symptoms in the intervention groups was 0.03 standard deviations lower (−0.43 lower to 0.37 higher) | |
|
TSH suppression (<0.4 mlU/L) cases |
160 (2 studies) 3 months |
⊕⊝⊝⊝ due to risk of bias, imprecision |
OR 8.12 (2.28 to 28.89) | 0 per 1000 |
80 more per 1000 (from 30 more to 130 more)3 |
- 1
Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs
- 2
Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias
- 3
zero events in both arms of one study and one arm of one study
Table 4Clinical evidence summary: T4 vs Placebo in older adults
| Outcomes | No of Participants (studies) Follow up | Quality of the evidence (GRADE) | Relative effect (95% CI) | Anticipated absolute effects | |
|---|---|---|---|---|---|
| Risk with Placebo in older adults | Risk difference with T4 (95% CI) | ||||
|
QoL EQ-5D. Scale from: −0.59 to 1. Better indicated by higher values. |
638 (1 study) 12 months |
⊕⊕⊕⊝ MODERATE1 due to imprecision |
The mean qol in the control groups was 0.85 |
The mean qol in the intervention groups was 0.02 lower (0.05 lower to 0.01 higher) | |
|
QoL EQ VAS. Scale from: 0 to 100. Better indicated by higher values. |
638 (1 study) 12 months |
⊕⊕⊕⊕ HIGH |
The mean qol in the control groups was 77.4 |
The mean qol in the intervention groups was 0.1 lower (2.38 lower to 2.18 higher) | |
|
Hypothyroid symptoms ThyPRO-hypothyroidism. Scale from: 0 to 100. |
638 (1 study) 12 months |
⊕⊕⊕⊕ HIGH |
The mean hypothyroid symptoms in the control groups was 16.7 |
The mean hypothyroid symptoms in the intervention groups was 0.1 lower (2.77 lower to 2.57 higher) | |
|
Hypethyroid symptoms ThyPRO hyperthyroidism. Scale from: 0 to 100. |
638 (1 study) 12 months |
⊕⊕⊕⊕ HIGH |
The mean hyperthyroid symptoms in the control groups was 10.3 |
The mean hyperthyroid symptoms in the intervention groups was 0.2 higher (1.52 lower to 1.92 higher) | |
- 1
Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs
Table 4UK costs of subclinical thyroid treatment
| Drug | Daily dose | Cost - month | Cost – annual |
|---|---|---|---|
| Levothyroxine (T4), 100µg | 100µg | £1.03 | £13.43 |
| Levothyroxine (T4), 75µg | 75µg | £2.10 | £27.38 |
| Levothyroxine (T4), 50µg | 50µg | £1.03 | £13.43 |
| Levothyroxine (T4), 25µg | 25µg | £1.63 | £21.25 |
Source: BNF, Date, August 2019
FINAL
Intervention evidence review underpinning recommendations 1.5.1 to 1.5.6 in the guideline
Developed by the National Guideline Centre, hosted by the Royal College of Physicians
Disclaimer: The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and, where appropriate, their carer or guardian.
Local commissioners and providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.
NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the Welsh Government, Scottish Government, and Northern Ireland Executive. All NICE guidance is subject to regular review and may be updated or withdrawn.